



Clinical trial results:

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2010-023237-37 |
| Trial protocol | DE |
| Global end of trial date | 31 March 2015 |

Results information

| | |
|-----------------------------------|---|
| Result version number | v1 (current) |
| This version publication date | 13 December 2021 |
| First version publication date | 13 December 2021 |
| Summary attachment (see zip file) | EVITA CSR SYNOPSIS (GBG 64 - E-VITA Clinical Study Report - Synopsis Version 2.pdf) |

Trial information

Trial identification

| | |
|-----------------------|-------|
| Sponsor protocol code | GBG64 |
|-----------------------|-------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01534455 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GBG Forschungs GmbH |
| Sponsor organisation address | Martin Behaim Str. 12, Neu-Isenburg, Germany, |
| Public contact | Medicine and Research, GBG Forschungs GmbH, +49 610274800, publications@gbg.de |
| Scientific contact | Medicine and Research, GBG Forschungs GmbH, +49 610274800, publications@gbg.de |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 22 March 2016 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 31 March 2015 |
| Global end of trial reached? | Yes |
| Global end of trial date | 31 March 2015 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

1. To assess the time to progression (TTP) of eribulin at a dose of 1.23 mg/m² IV days 1+8, q 21 and eribulin given at a dose of 1.76 mg/m² IV day 1, q d21 both in combination with lapatinib.
2. To assess the safety and toxicity of both treatment arms.

Protection of trial subjects:

The trial protocol including amendments, the patient information and the informed consent were reviewed and approved from a properly constituted IRB/IEC for each site prior to the study start. The trial was in compliance with the International Conference on Harmonization (ICH) - Harmonized Tripartite Guideline for Good Clinical Practice (GCP) (E6), and the Commission Directives in the European Community as well as with the applicable German national laws and regulations, and with Declaration of Helsinki and its revisions in all aspects of preparation, monitoring, reporting, auditing, and archiving. IDMC was to ensure the ethical conduct of the trial and to protect patients' safety interests in this study

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------------|
| Actual start date of recruitment | 23 January 2012 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Scientific research |
| Long term follow-up duration | 10 Years |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Germany: 41 |
| Worldwide total number of subjects | 41 |
| EEA total number of subjects | 41 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |

| | |
|---------------------------|----|
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 32 |
| From 65 to 84 years | 9 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Approximately 2.5years (Q-I 2012–Q-III 2014) in 49 sites in Germany. 43 pts were randomized, 41 started treatment (eribulin 1.23mg/m² d1,8: 21; eribulin 1.76mg/m² d1: 20). Study was amended in Nov 2013 to prolong recruitment for being behind planned schedule. Despite that, study was stopped on 7th July 2014 due to persistent difficulty in accrual.

Pre-assignment

Screening details:

Histologically HER2+ BC; Advanced BC not suitable for surgery or RT alone;

Previous systemic treatments eligible:

Adjuvant and ≤3 CT regimen for advanced BC;

Previous trastuzumab as (neo)adjuvant for eBC and/or 1st and/or 2nd line for mBC;

Prior max. cum. dose ≤ 360 mg/m² for A and 720 mg/m² for E;

ECOG 0-2, normal cardiac eject. function

Pre-assignment period milestones

| | |
|------------------------------|----|
| Number of subjects started | 41 |
| Number of subjects completed | 41 |

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|---------------|
| Arm title | Eribulin 1.23 |
|------------------|---------------|

Arm description:

Eribulin 1.23 mg/m² IV days 1+8, q d21

| | |
|--|-----------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Eribulin mesylate (Halaven) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Eribulin 1.23mg/m² IV as a bolus over 2-5 minutes, days 1+8, q d21

| | |
|------------------|---------------|
| Arm title | Eribulin 1.76 |
|------------------|---------------|

Arm description:

Eribulin 1.76 mg/m² IV day 1 q d21

| | |
|--|------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Eribulin mesylate (Halaven®) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Eribulin 1.76 mg/m² IV as a bolus over 2-5 minutes, day 1, q d21

| Number of subjects in period 1 | Eribulin 1.23 | Eribulin 1.76 |
|---|---------------|---------------|
| Started | 21 | 20 |
| Completed | 14 | 13 |
| Not completed | 7 | 7 |
| Physician decision | 2 | - |
| Adverse event, non-fatal | 1 | - |
| Hematological tox. related to study med | - | 1 |
| Other reasons | 2 | 3 |
| Patient wish | - | 1 |
| Non-hematol. tox. related to study med | 1 | 2 |
| death (not tumor-related) | 1 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Eribulin 1.23 |
|-----------------------|---------------|

Reporting group description:

Eribulin 1.23 mg/m² IV days 1+8, q d21

| | |
|-----------------------|---------------|
| Reporting group title | Eribulin 1.76 |
|-----------------------|---------------|

Reporting group description:

Eribulin 1.76 mg/m² IV day 1 q d21

| Reporting group values | Eribulin 1.23 | Eribulin 1.76 | Total |
|---|---------------|---------------|-------|
| Number of subjects | 21 | 20 | 41 |
| Age categorical Units: Subjects | | | |
| In utero | | | 0 |
| Preterm newborn infants (gestational age < 37 wks) | | | 0 |
| Newborns (0-27 days) | | | 0 |
| Infants and toddlers (28 days-23 months) | | | 0 |
| Children (2-11 years) | | | 0 |
| Adolescents (12-17 years) | | | 0 |
| Adults (18-64 years) | | | 0 |
| From 65-84 years | | | 0 |
| 85 years and over | | | 0 |
| Age continuous Units: years | | | |
| median | 50 | 60 | |
| full range (min-max) | 32 to 84 | 39 to 69 | - |
| Gender categorical Units: Subjects | | | |
| Female | 21 | 20 | 41 |
| Male | 0 | 0 | 0 |

End points

End points reporting groups

| | |
|--|---------------|
| Reporting group title | Eribulin 1.23 |
| Reporting group description: Eribulin 1.23 mg/m ² IV days 1+8, q d21 | |
| Reporting group title | Eribulin 1.76 |
| Reporting group description: Eribulin 1.76 mg/m ² IV day 1 q d21 | |

Primary: Time to progression (TTP)

| | |
|--|--|
| End point title | Time to progression (TTP) ^[1] |
| End point description: Time to progression (TTP) is defined as the time period between randomization and documented disease progression or disease-related death. Patients with no progression or tumor-related death reported were censored on the date of the last contact ("last tumor assessment", "last follow up date" or "last date in drug log"). | |
| End point type | Primary |
| End point timeframe: time in months between randomization and first event | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Kaplan-Meier estimates were presented graphically; median time to progression was reported in each arm together with the 95% confidence interval (CI). No test of significance was planned to compare treatment arms

| End point values | Eribulin 1.23 | Eribulin 1.76 | | |
|----------------------------------|-------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 21 ^[2] | 20 ^[3] | | |
| Units: month | | | | |
| number (confidence interval 95%) | 8.1 (4.8 to 9.4) | 6.5 (4.6 to 13.4) | | |

Notes:

[2] - 19events

[3] - 17events

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival

| | |
|--|------------------|
| End point title | Overall survival |
| End point description: Overall survival (OS) is defined as the time period between randomization and death due to any cause. Patients with no death reported were censored on the date of the last contact ("last tumor assessment", "last follow up date" or "last date in drug log"). | |
| End point type | Secondary |
| End point timeframe: time in months between randomization and death | |

| | | | | |
|----------------------------------|---------------------|---------------------|--|--|
| End point values | Eribulin 1.23 | Eribulin 1.76 | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 21 ^[4] | 20 ^[5] | | |
| Units: month | | | | |
| number (confidence interval 95%) | 23.1 (12.5 to 35.0) | 23.2 (13.7 to 30.1) | | |

Notes:

[4] - 14 events

[5] - 12 events

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All adverse events occurring during the study treatment period were reported

Adverse event reporting additional description:

Predefined AEs any grade (1-4) are reported per Patient.

Other AEs reported as free-text are given irrespective of preferred terms if occurring in >20%

For SAEs relatedness was not tabulated, therefore here we conservatively record all SAEs as related to treatment

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | n.a. |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Eribulin 1.23 |
|-----------------------|---------------|

Reporting group description:

Eribulin 1.23 mg/m² IV days 1+8, q d21

| | |
|-----------------------|---------------|
| Reporting group title | Eribulin 1.76 |
|-----------------------|---------------|

Reporting group description:

Eribulin 1.76 mg/m² IV day 1 q d21

| Serious adverse events | Eribulin 1.23 | Eribulin 1.76 | |
|---|-----------------|-----------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 6 / 21 (28.57%) | 8 / 20 (40.00%) | |
| number of deaths (all causes) | 1 | 1 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Gastric cancer | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Vascular disorders | | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deep vein thrombosis | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Arrhythmia | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 2 / 20 (10.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 3 / 21 (14.29%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 3 / 3 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 2 / 20 (10.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 2 / 21 (9.52%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fever | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 4 / 20 (20.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 4 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Flu like symptoms | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chills | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Macular edema | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal haemorrhage | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|----------------|----------------|--|
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Pulmonary mass | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in lumbar spine | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 21 (9.52%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Eribulin 1.23 | Eribulin 1.76 | |
|---|-------------------|-------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 21 / 21 (100.00%) | 20 / 20 (100.00%) | |
| Investigations | | | |
| Increased bilirubin | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 3 / 20 (15.00%) | |
| occurrences (all) | 1 | 3 | |
| Increased alkaline phosphatase | | | |
| subjects affected / exposed | 7 / 21 (33.33%) | 7 / 20 (35.00%) | |
| occurrences (all) | 7 | 7 | |

| | | | |
|---|------------------------|------------------------|--|
| Increased ASAT subjects affected / exposed occurrences (all) | 13 / 21 (61.90%) 13 | 15 / 20 (75.00%) 15 | |
| Increased ALAT subjects affected / exposed occurrences (all) | 15 / 21 (71.43%) 15 | 12 / 20 (60.00%) 12 | |
| Increased creatinine subjects affected / exposed occurrences (all) | 1 / 21 (4.76%) 1 | 1 / 20 (5.00%) 1 | |
| Vascular disorders Vascular disorders subjects affected / exposed occurrences (all) | 4 / 21 (19.05%) 4 | 8 / 20 (40.00%) 8 | |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 4 / 21 (19.05%) 4 | 6 / 20 (30.00%) 6 | |
| Sensory neuropathy subjects affected / exposed occurrences (all) | 13 / 21 (61.90%) 13 | 14 / 20 (70.00%) 14 | |
| Nervous system disorder subjects affected / exposed occurrences (all) | 5 / 21 (23.81%) 5 | 5 / 20 (25.00%) 5 | |
| Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) | 18 / 21 (85.71%) 18 | 15 / 20 (75.00%) 15 | |
| Leukopenia subjects affected / exposed occurrences (all) | 19 / 21 (90.48%) 19 | 17 / 20 (85.00%) 17 | |
| Neutropenia subjects affected / exposed occurrences (all) | 16 / 21 (76.19%) 16 | 16 / 20 (80.00%) 16 | |
| Febrile neutropenia subjects affected / exposed occurrences (all) | 1 / 21 (4.76%) 1 | 2 / 20 (10.00%) 2 | |
| Thrombopenia | | | |

| | | | |
|---|----------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 6 / 21 (28.57%) 6 | 2 / 20 (10.00%) 2 | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 16 / 21 (76.19%) | 16 / 20 (80.00%) | |
| occurrences (all) | 16 | 16 | |
| Mucositis/esophagitis | | | |
| subjects affected / exposed | 9 / 21 (42.86%) | 10 / 20 (50.00%) | |
| occurrences (all) | 9 | 10 | |
| Fever without neutropenia | | | |
| subjects affected / exposed | 5 / 21 (23.81%) | 6 / 20 (30.00%) | |
| occurrences (all) | 5 | 6 | |
| General disorders and administration site conditions | | | |
| subjects affected / exposed | 3 / 21 (14.29%) | 11 / 20 (55.00%) | |
| occurrences (all) | 3 | 11 | |
| Immune system disorders | | | |
| Allergic reactions | | | |
| subjects affected / exposed | 5 / 21 (23.81%) | 6 / 20 (30.00%) | |
| occurrences (all) | 5 | 6 | |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 10 / 21 (47.62%) | 9 / 20 (45.00%) | |
| occurrences (all) | 10 | 9 | |
| Vomiting | | | |
| subjects affected / exposed | 6 / 21 (28.57%) | 4 / 20 (20.00%) | |
| occurrences (all) | 6 | 4 | |
| Diarrhoea | | | |
| subjects affected / exposed | 12 / 21 (57.14%) | 12 / 20 (60.00%) | |
| occurrences (all) | 12 | 12 | |
| Constipation | | | |
| subjects affected / exposed | 3 / 21 (14.29%) | 4 / 20 (20.00%) | |
| occurrences (all) | 3 | 4 | |
| Gastrointestinal disorders | | | |
| subjects affected / exposed | 10 / 21 (47.62%) | 9 / 20 (45.00%) | |
| occurrences (all) | 10 | 9 | |
| Respiratory, thoracic and mediastinal | | | |

| | | | |
|---|------------------|------------------|--|
| disorders | | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| subjects affected / exposed | 5 / 21 (23.81%) | 14 / 20 (70.00%) | |
| occurrences (all) | 5 | 14 | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 20 / 21 (95.24%) | 18 / 20 (90.00%) | |
| occurrences (all) | 20 | 18 | |
| PPE (hand-foot syndrome) | | | |
| subjects affected / exposed | 7 / 21 (33.33%) | 5 / 20 (25.00%) | |
| occurrences (all) | 7 | 5 | |
| Skin and subcutaneous tissue disorders | | | |
| subjects affected / exposed | 13 / 21 (61.90%) | 14 / 20 (70.00%) | |
| occurrences (all) | 13 | 14 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 10 / 21 (47.62%) | 12 / 20 (60.00%) | |
| occurrences (all) | 10 | 12 | |
| Myalgia | | | |
| subjects affected / exposed | 6 / 21 (28.57%) | 7 / 20 (35.00%) | |
| occurrences (all) | 6 | 7 | |
| Musculoskeletal, connective tissue and bone disorders | | | |
| subjects affected / exposed | 5 / 21 (23.81%) | 9 / 20 (45.00%) | |
| occurrences (all) | 5 | 9 | |
| Infections and infestations | | | |
| Infection | | | |
| subjects affected / exposed | 11 / 21 (52.38%) | 10 / 20 (50.00%) | |
| occurrences (all) | 11 | 10 | |
| Metabolism and nutrition disorders | | | |
| Anorexia | | | |
| subjects affected / exposed | 5 / 21 (23.81%) | 7 / 20 (35.00%) | |
| occurrences (all) | 5 | 7 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|---|
| 11 September 2013 | <p>There was one substantial Amendment to the protocol of E-Vita.</p> <p>In November 2013, given that the study recruitment was behind the planned schedule, the study was amended in order to prolong the recruitment period, as well as to allow the use of new Anti-HER2 treatment options as TDM1.</p> <p>Despite that the study was stopped in July 2014 due to the persistent difficulty in accrual.</p> <p>Amendment 1 protocol changes:</p> <p>Title: A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in patients pre-treated with anti-HER2- therapy with HER2-positive metastatic breast cancer.</p> <p>Stratification factors for randomization will be:</p> <ul style="list-style-type: none">• previous line of chemotherapy for metastatic disease (0-1 vs. 2-3). <p>Inclusion criterion no.6:</p> <p>The following previous systemic treatments are eligible:</p> <ul style="list-style-type: none">• Previous treatment with anti HER2 therapy either as (neo)adjuvant treatment for early breast cancer and/or first, second and/or third line treatment for metastatic breast cancer,• adjuvant and up to 3 chemotherapy regimen for metastatic breast cancer,...• radiotherapy with full recovery from clinical relevant side effects. The measurable disease must be completely outside the radiation field or there must be pathologic proof of progressive disease. <p>Exclusion criterion no.2:</p> <p>Patients who have received eribulin or who have received lapatinib as part of the last therapy before entering this Trial.</p> <p>Enrollment period: 36 months (Q-I 2012 – Q-I 2015).</p> <p>Regular End of Study: The end of this study is defined as 4 years after the 1st patient entered the trial. Planned end of study is Q-I 2016.</p> |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/30875348>